Medtech Sector

India’s pharmaceutical and medical technology (MedTech) sectors are closely monitoring the Union Budget 2026, anticipating policy measures that could accelerate innovation, enhance domestic manufacturing, and expand global competitiveness. Industry stakeholders expect incentives for research and development, tax breaks for high-value manufacturing, and support for technology adoption in healthcare delivery.

India’s medtech sector is poised for accelerated growth, driven by government incentives under the Production-Linked Incentive (PLI) scheme and reforms in raw material procurement. The PLI program aims to enhance domestic manufacturing, reduce import dependence, and encourage exports of high-value medical devices. Simultaneously, easier access to critical raw materials is expected to improve production efficiency and cost competitiveness. Industry experts predict that these combined measures will not only strengthen the supply chain but also position India as a global medtech hub.